Resveratrol is a naturally occurring polyphenol that provides a number of anti-aging health benefits including improved metabolism, cardioprotection, and cancer prevention. Resveratrol appears to have many anti-tumor effects on different cancer cells in vitro and these effects and pathways have been extensively reviewed. Although in vitro and animal experimental data are extremely promising for resveratrol's anti-proliferative effects, there is limited development regarding its use in clinical settings. One problem with this translation is the limited bioavailability of resveratrol as it is metabolically eliminated from the body extremely fast, so much so that it is difficult to maintain a therapeutically relevant level in the bloodstream. Here we show that undecylenic acid-based nanocarriers can significantly improve total resveratrol concentration over time in aqueous solutions of oxidizing enzyme. Each of the nanocarriers increased the initial solubility of the resveratrol and decreased the enzymatic degradation rate constant. These results are consistent with an earlier study with the experimental drug RAC1, a synthetic polyphenol, and poly(undecylenic acid) nanocarriers. The solubilization enhancement and protection from enzymatic metabolism offered by the undecylenic acid-based nanocarriers should extend to other natural and synthetic, small molecule, cytotoxic agents and offer an accessible platform for in vivo studies of promising anti-cancer drug candidates.

Undecylenic acid-based nanocarriers for resveratrol chemotherapy

256th National Meeting (2018)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.